Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New Data Presented at ECTRIMS Reinforce Long-term Benefits of Tecfidera Over 10 Years

Biogen Inc. announced new data to support the consistent, long-term benefits of treatment with Tecfidera (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis.

Read More »

U.S. prices for multiple sclerosis drugs are on the rise

A U.S. study suggests that annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market.

Read More »

Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial

In a Phase III head-to-head trial, Janssen Pharmaceutical’s ponesimod stood up to Sanofi’s Aubagio (teriflunomide) in adults with relapsing multiple sclerosis.

Read More »

Scientists Identify Differences Between Relapsing/Remitting and Progressive Multiple Sclerosis

Researchers with City University of New York and the Icahn School of Medicine at Mount Sinai identified specific biological differences between relapsing-remitting MS (RRMS) – in which patients often go into clinical remission – and progression MS, which has the potential to lead to new therapeutic approaches and diagnostic testing.

Read More »

Genentech Strikes Three Drug Discovery Deals

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

Read More »

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

New interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that Biogen’s investigational treatment diroximel fumarate was generally well tolerated in people with relapsing MS.

Read More »

Novartis data at AAN show Gilenya is only disease-modifying therapy with proven superiority versus glatiramer acetate in RRMS

Novartis announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

Read More »

Teva migraine drug helps to contain profit fall

Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter 2019 profit and forecast a sharp rise in 2020 revenue from the company’s new migraine drug Ajovy.

Read More »

FDA Green-Lights EMD Serono’s Mavenclad

EMD Serono, a unit of Merck KGaA, announced that the U.S. FDA approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis and active secondary progressive disease.

Read More »

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Celgene Corporation announced that the company submitted a New Drug Application to the U.S. FDA for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS).

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom